Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285490 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
A Phase 3 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT03285490: Completed Phase 3 study, sponsored by Almirall, S.A..
NCT03285490 is a Phase 3 study that has completed, run by Almirall, S.A.. The registered enrollment target is 351 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03285490, a Phase 3 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.
Primary Outcome
Complete clearance rate was defined as the percentage of participants at Day 57 with no clinically visible AK lesions in the treatment area.
Interventions
- DRUG Placebo
- DRUG KX2-391 Ointment 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2019-04-24 |
| Phase | Phase 3 |
What the finished NCT03285490 record still lists
NCT03285490 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03285490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03285490 about?
NCT03285490 is a clinical study titled "A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)". This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.
What is the current status of trial NCT03285490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2017-09-15. Estimated completion is 2019-04-24.
What interventions are being tested in trial NCT03285490?
The interventions under investigation include: Placebo (DRUG), KX2-391 Ointment 1% (DRUG).
Who is sponsoring clinical trial NCT03285490?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03285490's enrollment target sits among peer trials
351 1033rd of 2000 higher than 967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI